Tag: peptide receptor radionuclide therapy
![glucomedix1](https://www.carcinoid.org/wp-content/uploads/2011/03/glucomedix1.jpg)
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE![staff sergeant daniel barber helicopter](https://www.carcinoid.org/wp-content/uploads/2010/09/staff-sergeant-daniel-barber-helicopter.jpg)
A Carcinoid Soldier’s Survivor Story
When Staff Sergeant Daniel Barber of D Company 1-106th AVN in the Missouri National Guard was first diagnosed with carcinoid cancer in 2009 he experienced feelings of shock, despair, anger, fear and frustration. But he was also relieved because he knew…
READ MORE![ebrahim s delpassand md facnm](https://www.carcinoid.org/wp-content/uploads/2010/08/ebrahim-s-delpassand-md-facnm.jpg)
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE